Drug Eluting Balloon Market Overview

Drug Eluting Balloon (DEB) is a type of angioplasty balloon coated with anti-proliferative drugs that are released into the vessel wall during balloon inflation. These balloons are widely used in interventional cardiology and vascular treatments to reduce restenosis and improve blood circulation in blocked or narrowed arteries.

The market is witnessing strong growth due to the rising prevalence of vascular diseases and increasing demand for minimally invasive procedures. Patients and healthcare providers are increasingly preferring minimally invasive treatments due to reduced pain, shorter hospitalization periods, and faster recovery rates.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2321

The global drug eluting balloon market was valued at US$ 571.1 Mn in 2022 and is projected to reach US$ 1.0 Bn by the end of 2031, expanding at a CAGR of 7.1% from 2023 to 2031. Market growth is driven by the increasing prevalence of cardiovascular disorders, rising geriatric population, and growing adoption of minimally invasive vascular procedures.

Analysis of Key Players in the Drug Eluting Balloon Market

The global drug eluting balloon market is highly competitive, with leading companies focusing on product innovation, strategic acquisitions, and expansion of interventional cardiology portfolios.

Key companies operating in the market include:

• Bayer AG
• Medtronic
• B. Braun Melsungen AG
• Cook Medical, Inc.
• Boston Scientific Corporation
• Becton, Dickson and Company
• EuroCor
• Terumo Corporation
• Koninklijke Philips N.V.
• Other Prominent Players

These players are investing in advanced drug-coated balloon technologies, targeted drug delivery systems, and minimally invasive treatment solutions to strengthen their market position and expand their global footprint.

Key Developments in Global Drug Eluting Balloon Market

• On October 2, 2023, Cordis, a global leader in development and manufacture of interventional cardiovascular and endovascular technology, announced the acquisition of MedAlliance, a Switzerland-based developer of drug-eluting balloon technology. The acquisition is likely to improve the company’s coronary and peripheral vascular product portfolio.
• On August 9, 2023, Boston Scientific Corporation, a leading manufacturer of innovative medical solutions, announced it had received the U.S. Food and Drug Administration (FDA) approval for the POLARx Cryoablation System. This is a new system with unique capability of enabling two balloon sizes – 28 and 31mm – in one catheter.

Analysts’ Viewpoint on the Global Drug Eluting Balloon Market

Industry analysts highlight that the increasing burden of cardiovascular diseases and peripheral artery disease (PAD) is significantly driving demand for drug eluting balloons worldwide. The growing aging population, combined with rising incidences of obesity, diabetes, and hypertension, is further accelerating market expansion.

The shift toward minimally invasive and catheter-based procedures is transforming vascular treatment approaches. Drug eluting balloons are gaining preference due to their ability to reduce restenosis risk and improve long-term treatment outcomes without leaving permanent implants in arteries.

North America dominates the market due to advanced healthcare infrastructure, high diagnosis rates, and favorable reimbursement policies, while Asia Pacific is emerging as a rapidly growing market due to increasing healthcare investments and rising prevalence of cardiovascular disorders.

👉 Discuss Implications for Your Industry or Do you want customize Report, Please Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2321

Key Player Strategies

⚙️ Product Innovation
Development of next-generation drug-coated balloon technologies

🌐 Strategic Acquisitions
Expansion of cardiovascular and vascular treatment portfolios

🏥 Clinical Advancements
Focus on minimally invasive and image-guided procedures

🔬 R&D Investments
Enhancement of targeted drug delivery systems and catheter technologies

🌍 Global Expansion
Strengthening presence in emerging healthcare markets

Challenges

• High cost associated with advanced cardiovascular procedures
• Stringent regulatory approval processes for medical devices
• Risk of restenosis and treatment complications in certain patients
• Limited accessibility in low-income healthcare systems

Opportunities

⚡ Rising Demand for Minimally Invasive Procedures
Increasing preference for catheter-based vascular treatments

🏃 Growing Aging Population
Higher incidence of PAD and cardiovascular diseases among elderly patients

🌱 Advancements in Interventional Cardiology
Development of innovative drug delivery and imaging technologies

🏥 Expansion of Healthcare Infrastructure
Growing investments in hospitals and cardiac care centers

🌍 Emerging Markets Growth
Increasing adoption of advanced vascular treatments in Asia Pacific and Latin America

Market Segmentation

By Product Type

• Coronary Drug Eluting Balloon
• Peripheral Drug Eluting Balloon

By End-user

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

By Application

• Coronary Artery Disease
• Peripheral Artery Disease
• Others

By Region

• North America – Advanced healthcare infrastructure and reimbursement support
• Europe – Strong adoption of minimally invasive cardiovascular treatments
• Asia Pacific – Rapidly growing patient population and healthcare investments
• Latin America
• Middle East & Africa

Regional Outlook

North America is expected to hold the largest share of the drug eluting balloon market during the forecast period due to high diagnosis rates, developed healthcare infrastructure, and favorable reimbursement policies for cardiovascular treatments. Rising prevalence of peripheral artery disease and heart disorders is also supporting market growth in the region.

Asia Pacific is projected to witness steady growth due to the increasing patient population, rising prevalence of diabetes and obesity, and growing demand for minimally invasive procedures. Countries such as China and India are investing heavily in healthcare infrastructure and cardiovascular care, thereby driving market expansion.

Europe also represents a significant market owing to increasing adoption of advanced angioplasty technologies and supportive healthcare systems. Meanwhile, Latin America and the Middle East & Africa are expected to witness gradual growth with improving access to cardiovascular treatments.

Why Invest in the Drug Eluting Balloon Market Analysis 2031

✅ Strong market growth driven by increasing cardiovascular disease prevalence

✅ Rising demand for minimally invasive and catheter-based treatments

✅ Continuous advancements in targeted drug delivery technologies

✅ Growing aging population and increasing PAD cases

✅ Expanding healthcare investments in emerging economies

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=2321&ltype=S

FAQs

1. What is the projected market size by 2031?

The market is expected to reach US$ 1.0 Bn by the end of 2031.

2. What is the CAGR of the market?

The market is projected to grow at a CAGR of 7.1% from 2023 to 2031.

3. What factors are driving market growth?

Key drivers include rising prevalence of vascular diseases, increasing adoption of minimally invasive procedures, and growth in the aging population.

4. Which region dominates the market?

North America dominates the market due to advanced healthcare infrastructure and favorable reimbursement policies.

5. What are the key trends in the market?

Major trends include advancements in drug-coated balloon technologies, growth in minimally invasive surgeries, and increasing investments in cardiovascular care.

More Trending Reports by Transparency Market Research –

Radiodermatitis Market: https://www.transparencymarketresearch.com/radiodermatitis-market.html

Anti-Inflammatory Therapeutics Market: https://www.transparencymarketresearch.com/anti-inflammatory-therapeutics-market.html

South America Equine Supplement Market: https://www.transparencymarketresearch.com/south-america-equine-supplement-market.html

CINV Existing and Pipeline Drugs Market: https://www.transparencymarketresearch.com/cinv-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com